Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours Β· Estimated delivery Aug 19 - Aug 24
95% CI 2.46, 7.53
Efficacy estimand This estimand is used to assess the average treatment effect of bimagrumab, semaglutide or bimagrumab plus semaglutide for all randomized participants at weeks 48 and 72 had they received at least one dose of study treatment, adhered to protocol-defined treatment and did not discontinue treatment prematurely
Similar content being viewed by others Introduction/background Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are a class of medications increasingly utilized in the treatment of type 2 diabetes and, more recently, obesity (Nathan et al
The higher 3.0 mg and 4.5 mg doses that were approved in 2020 demonstrated hemoglobin A1c reductions closer to 1.5% and slightly more weight loss
GLP-1 delays gastric emptying and prolongs the feeling of fullness, while GCG increases satiety and reduces calorie intake
US$ 25.49
US$ 22.60
US$ 24.86
US$ 23.56
